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Aims Medication non-adherence is frequent and is associated with high morbidity and mortality in patients with chronic
heart failure (CHF). We investigated whether an interdisciplinary intervention improves adherence in elderly CHF
patients.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
The study population (mean age 74 years, 62% male, mean left ventricular ejection fraction 47%, 52% in New York
Heart Association class III) consisted of 110 patients randomized into the pharmacy care and 127 into the usual
care group. The median follow-up was 2.0 years (interquartile range 1.2–2.7). The pharmacy care group received
a medication review followed by regular dose dispensing and counselling. Control patients received usual care.
The primary endpoint was medication adherence as proportion of days covered (PDC) within 365 days for three
classes of heart failure medications (beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor
blockers, and mineralocorticoid receptor antagonists). The main secondary outcome was the proportion of adherent
patients (PDC≥ 80%). The primary safety endpoint was days lost due to unplanned cardiovascular hospitalizations
(blindly adjudicated) or death. Pharmacy care compared with usual care resulted in an absolute increase in mean
adherence to three heart failure medications for 365 days [adjusted difference 5.7%, 95% confidence interval (CI)
1.6–9.8, P = 0.007]. The proportion of patients classified as adherent increased (odds ratio 2.9, 95% CI 1.4–5.9,
P = 0.005). Pharmacy care improved quality of life after 2 years (adjusted difference in Minnesota Living with Heart
Failure Questionnaire scores −7.8 points (−14.5 to −1.1; P = 0.02), compared to usual care. Pharmacy care did not
affect the safety endpoints of hospitalizations or deaths.
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Conclusion Pharmacy care safely improved adherence to heart failure medications and quality of life.
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Introduction
Heart failure (HF) is an increasingly prevalent condition, limit-
ing functional capacity associated with impaired quality of life
and mortality imposing a high burden on health care systems.1
Guideline-directed pharmacotherapy decreases morbidity and
mortality in patients with HF with reduced ejection fraction.
Guidelines recommend the use of diuretics for symptom relief and
appropriate management of co-morbidities in patients with HF
with preserved or mid-range ejection fraction.2 Non-adherence
to pharmacotherapy, however, affects 20–50% of all patients,
and affects morbidity and mortality in patients with chronic HF
(CHF).3–5 Patients with CHF often receive additional drugs
for co-morbidities leading to polypharmacy with an increased
risk of drug-related problems (DRPs).6,7 DRPs are potentially
preventable by interdisciplinary advise involving physicians and
pharmacists. These efforts appear to be successful when the
pharmacist acts as part of a multidisciplinary team.8 However,
there are no pharmacy-based randomized controlled trials (RCT)
aiming to improve medication adherence in elderly CHF patients
by structured, regular and long-term patient contacts. HF is
associated with impaired quality of life (QoL), but few RCTs have
provided evidence with regard to interventions improving QoL.9
PHARM-CHF investigated whether an interdisciplinary interven-
tion consisting of regular contacts with the local pharmacy and
weekly dosing aids improves medication adherence and QoL in
elderly patients with CHF, and whether it affects hospitalizations
and mortality.
Methods
Study design and participants
PHARM-CHF was an investigator-initiated, prospective multicentre,
randomized controlled study. The study design has been published
previously.10 In brief, patients aged 60 years and older with CHF defined
by HF symptoms, currently treated with a diuretic, and a hospitalization
for HF within the last 12months or increased B-type natriuretic
peptide or N-terminal pro-B-type natriuretic peptide concentrations,
were recruited by study physicians. After choosing the attending
community pharmacy, patients were randomized via a secure web
interface tool (www.pharm-chf.de) in a 1:1 ratio to the intervention
(pharmacy care) or control group (usual care). The PHARM-CHF
trial was conducted according to the principles stated in the current
version of the Declaration of Helsinki, International Conference on
Harmonization (ICH) Good Clinical Practice (GCP), and to local and
national regulations. Documented approvals from independent ethics
committees were obtained for all participating centres and written
informed consent from all patients. The study is registered with
ClinicalTrials.gov, identifier: NCT 01692119.
Study protocol
Details on study visits, data collection, intervention, and standardiza-
tion were previously described.10 In brief, the intervention consisted of
the following components: first, medication review (Type 2a according
to the Pharmaceutical Care Network Europe (PCNE) classification11) ..
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.. in the community pharmacy at baseline with the aim of generating a
consolidated medication plan. This included the following:
• compilation of the patient’s entire medication (based on the physi-
cian’s medication list, documented drug dispensing in the pharmacy,
and patient interview in the pharmacy),
• check for DRPs such as drug interactions and double medications
using a standardized check-list, and
• contact with the physician to discuss problems and risks if
necessary.
Based on the subsequently consolidated medication plan, the patient
received a weekly dosing aid together with a printout of the medication
plan. The type of the dosing aid (dosette, pill-box) was at the discretion
of the pharmacist and in agreement with the patient. Pharmacy care
continued by (bi-)weekly visits to the local pharmacy including:
• updating the medication plan if necessary,
• receiving the supply of medicines in dosing aids filled by the
pharmacist for 1 or 2weeks,
• counselling regarding medication, adherence, potential side effects,
signs and symptoms of decompensation,
• measurement of blood pressure and pulse rate,
• in case of newly detected DRP and/or significant changes in vital
signs, contact with the physician.
Patients in the usual care group continued to visit pharmacies of
their choice to fill prescriptions without further intervention. Usual
care mainly consisted of dispensing prescribed medication, including
counselling by the pharmacist or pharmacy technician on the safe
and appropriate use of the drug. Medication review, measuring blood
pressure and pulse rate or providing medication in a weekly dosing aid
are neither part of usual care nor reimbursed.
Study endpoints
The primary efficacy endpoint was medication adherence, defined
as a significant difference between the pharmacy care and usual
care groups using pharmacy claims data during the 365 days follow-
ing randomization for three HF medication classes [beta-blockers,
angiotensin-converting enzyme inhibitors (ACEi) or angiotensin
receptor blockers (ARB), and mineralocorticoid receptor antago-
nists (MRA)] prescribed at baseline. Adherence was calculated using
the proportion of days covered (PDC), which is the ratio of number
of days in the period covered by a medicine (numerator) to the total
number of days in the observation period (denominator).
The main secondary efficacy endpoint was the proportion of
patients classified as adherent (mean PDC≥ 80%). We further anal-
ysed the PDC for each drug class (beta-blockers, ACEi/ARB, MRA),
and the percentages of patients with a PDC≥ 80% for each drug class
for the periods of 365 as well as 730 days post-randomization.
Data collection, use of information and calculating the PDC were
the same in both groups and for all time-periods analysed. Health
insurance companies and data processing centres provided claims
data of prescribed drugs, dispensed at community pharmacies. These
data included information on the active ingredient(s), the dosage per
unit (strength), the package size, and the dispensing date. For all
patients, the information on the daily dose documented by the study
physician in the electronic case report form was used. Medication
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Trial flowchart. mITT, modified intention to treat population.
switches, stockpiling, hospital stays, medication fills prior to random-
ization, and death were considered. To measure baseline adherence,
the PDC for the period 183 days before randomization was analysed.
In case of inpatient days, the proportion was adjusted by exclud-
ing days from both the numerator and denominator assuming that
patients did not deplete their medication on their medication supply
on those excluded days. If a patient switched medications within a class
(including ACEi/ARB), the patient’s medication supply was replaced
with the new medication supply. If a patient died, all days follow-
ing the death were censored. Existing medication at randomization
and medication dispensed during 14 days after randomization were
considered if at least one additional dispensing occurred during the
365-day follow-up. Existing medication at randomization was captured,
but only the days during the 365-day follow-up contributed to the
final proportion.
Other secondary efficacy endpoints included QoL, depression, and
Patient Global Assessment (PGA). QoL was measured by the Min-
nesota Living with Heart Failure Questionnaire (MLHFQ) at baseline,
and after 12 and 24months. Depression was assessed using the 9-item
Patient Health Questionnaire (PHQ-9).12 Patients were characterized
(dichotomized) as non-depressed (<10 points) and as suspected to
currently have depression (≥10 points).
The primary composite safety endpoint was days lost due to
unplanned cardiovascular hospitalizations (blindly adjudicated) or
all-cause death. Secondary safety endpoints were percentage of days
lost due to unplanned cardiovascular hospitalizations or death of any
cause, all-cause mortality or unplanned cardiovascular hospitaliza-
tions as recurrent event, unplanned cardiovascular hospitalizations,
unplanned hospitalizations for HF, days lost due to hospitalizations of
any cause or death, unplanned all-cause hospitalizations, and all-cause
mortality.10
Sensitivity analyses
Pre-specified subgroup analyses were performed for age, sex, New
York Heart Association class, level of illness burden, diabetes,
depression, heart rate, HF medication, time between last HF hospital-
ization and randomization, and QoL as previously defined.10 ..
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. Statistical analyses
Assuming a mean PDC before randomization of approximately 70%,
a sample size of 176 patients (88 per group) was calculated to detect
a 10% [standard deviation (SD) 22%] improvement of the mean PDC
between the intervention and the usual care group with a power of 85%
and an alpha of 5%.10
The primary and secondary efficacy and safety analyses were
performed as described. Baseline characteristics are summarized as
number of patients (%) for categorical variables and as mean (SD) or
median [interquartile range (IQR)] for continuous variables. For con-
tinuous variables such as the PDC or the MLHFQ score, changes in
means of both study groups at 12 and 24months were compared by
ANCOVAmodels adjusted for the baseline value. Odds ratios (OR) for
a PDC ≥ 80% between groups were calculated via logistic regression,
adjusting for the baseline PDC. All statistical analyses were performed
using SAS version 9.4 (SAS Institute, Cary, NC, USA). PDC calculations
were performed using Microsoft SQL 2016.
Results
The study was performed at 31 sites (general practitioners, internal
medicine specialists, and both office- and hospital-based cardiolo-
gists) and 69 community pharmacies in nine different Federal States
of Germany.10 In total, 258 patients were recruited between Octo-
ber 2012 and January 2016, and 130 were randomized to the
pharmacy care group and 128 into the usual care group. In this
interdisciplinary study, randomization was performed by the physi-
cian without involvement of a pharmacist but the intervention was
delivered by the pharmacy. Three patients in the pharmacy care and
one patient in the usual care group were excluded because of major
protocol violations (i.e. patients were not prescribed a diuretic
as required).10 Furthermore, due to the nature of the pharmacy
care intervention, we defined the intention to treat (ITT) analyses
as those who completed randomization by attending their phar-
macy – a modified ITT (mITT). For various reasons, 17 patients
randomized into the pharmacy care group by their physician did not
present to a participating pharmacy. According to the pre-specified
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics of the participants in
the PHARM-CHF study
Characteristic Pharmacy
care (n = 110)
Usual care
(n = 127)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Demographics
Age, years, mean± SD 74.1± 6.8 74.1± 7.2
Female sex, n (%) 42 (38) 49 (39)
Physical examination, mean± SD
BMI, kg/m2 29.0± 5.2 29.2± 4.9
Systolic blood pressure,
mmHg
127.1±17.0 129.4±15.5
Diastolic blood pressure,
mmHg
76.0±10.9 77.3± 9.9
Heart rate, b.p.m. 73.5±13.2 75.8±13.8
Heart failure characteristics
Heart failure aetiology, n (%)
Ischaemic 65 (59) 61 (48)
Non-ischaemic 36 (33) 49 (39)
Other 9 (8) 17 (13)
LVEFa, %, mean± SD
(n = 91/104)
47.1±15.1 46.4±14.1
LVEF < 40%, n (%) 27 (25) 31 (24)
LVEF 40–49%, n (%) 40 (36) 49 (39)
LVEF ≥ 50%, n (%) 43 (39) 47 (37)
NYHA class, n (%)
I 7 (6) 6 (5)
II 38 (35) 46 (36)
III 58 (53) 65 (51)
IV 7 (6) 10 (8)
Medical history
Different co-morbidities,
mean± SD
7.4± 2.5 6.9± 2.2
Hypertension, n (%) 107 (97) 124 (98)
CAD, n (%) 80 (73) 85 (67)
Hyperlipidaemia, n (%) 90 (82) 95 (75)
Cardiomyopathy, n (%) 40 (36) 51 (40)
Valvular disease, n (%) 51 (46) 58 (46)
Atrial fibrillation, n (%) 63 (57) 81 (64)
Chronic renal disease, n (%) 50 (45) 45 (35)
Diabetes mellitus, n (%) 58 (53) 67 (53)
Myocardial infarction, n (%) 32 (29) 33 (26)
Stroke/TIA, n (%) 22 (20) 18 (14)
Sleep apnoea, n (%) 15 (14) 11 (9)
Depression, n (%) 18 (16) 19 (15)
COPD, n (%) 32 (29) 33 (26)
Treatments, n (%)
ICD or CRT* 44 (40) 31 (24)
Medication, n (%)
ACEi/ARB 86 (78) 106 (83)
Beta-blocker 100 (91) 121 (95)
MRA 49 (45) 52 (41)
Diureticb 110 (100) 127 (100)
Loop diuretic 87 (79) 106 (83)
Cardiac glycoside 17 (15) 16 (13)
Lipid-modifying agent 74 (67) 80 (63)
Antithrombotic agent 98 (89) 115 (91)
Antidepressant 6 (5) 14 (11)
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.. Table 1 Continued
Characteristic Pharmacy
care (n = 110)
Usual care
(n = 127)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Oral antidiabetic/insulin 35 (32) 39 (31)
No. drug packages, mean± SD 8.8± 3.0 8.9± 3.2
No. single doses per day,
mean± SD
10.7± 3.8 11.0± 4.3
No. drug intakes per day,
median (IQR)
3.0 (2–3) 3.0 (2–3)
Laboratory measurements, mean± SD
Serum creatinine, mg/dL 1.37± 0.51 1.34± 0.77
eGFR, mL/min 59.6± 25.6 62.9± 24.7
LDL-cholesterol, mg/dL 107.3± 35.8 110.4± 42.3
Blood urea nitrogen**, mg/dL 60.6± 29.5 52.0± 23.6
Quality of life (MLHFQc),
mean± SD
39.9±19.9 42.5± 22.3
Depression (PHQ-9d),
mean± SD
6.2± 4.9 7.4± 5.6
PHQ-9 score≥10, n (%) 25 (23) 35 (28)
Medication adherence (mean
PDCe) mean± SD
(n = 88/109)
68.1± 29.7 68.5± 27.6
Patients with mean PDC≥ 80%e,
n (%)
39 (44) 46 (42)
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; BMI, body mass index; CAD, coronary artery disease; COPD, chronic
obstructive pulmonary disease; CRT, cardiac resynchronization therapy; eGFR,
estimated glomerular filtration rate (Cockcroft–Gault formula); ICD, implantable
cardioverter-defibrillator; IQR, interquartile range; LDL, low-density lipopro-
tein; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor
antagonist; MLHFQ, Minnesota Living with Heart Failure Questionnaire; NYHA,
New York Heart Association; PDC, proportion of days covered; PHQ-9, 9-item
Patient Health Questionnaire; QoL, quality of life; SD, standard deviation; TIA,
transient ischaemic attack.
*P = 0.01.
**P = 0.02.
aAccording to available chart data.
bMRAs were considered as diuretics.
cMLHFQ total score: 0 = best QoL, 105 = worst QoL.
dPatients with a score ≥ 10 are suspected to currently have depression.
eMean PDC for beta-blockers, ACEi/ARB, and MRAs for the 183 days before
randomization.
analytical plan in the study protocol,10 these individuals were not
included in the analyses. A comprehensive statistical comparison
showed no relevant differences between these individuals com-
pared to the 110 patients included in the pharmacy care cohort
of the mITT population (Figure 1). Patients in the mITT popula-
tion had a mean (±SD) age of 74.1± 7.0 years (median 75.0, range
60–88) and 62% were male. The median number of drugs used was
nine and the mean baseline PDC for three HF medication classes
was 68%. Both groups had similar baseline characteristics (Table 1).
The median follow-up was 2.0 years (IQR 1.2–2.7). Median adher-
ence to the intervention during this time was 96% (IQR 84–100),
considering the weeks where medication was dispensed. Patients
visited the pharmacies with a median interval of 8.4 days (IQR
8.0–10.3).
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Adherence to heart failure medications between the pharmacy care and usual care groups
Variable Days
post-randomization
Pharmacy
care
(n = 90)
Usual
care
(n = 112)
Intervention
effecta
(95% CI)
Odds
ratiob
(95% CI)
NNT P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mean PDC (PEP), mean ± SDc 365 91.2±11.9 85.5± 16.6 5.7 (1.6–9.8) NA NA 0.007
730 87.2±15.4 83.5± 17.7 3.4 (−1.2–8.1) NA NA 0.15
Mean PDC ≥ 80%, n (%)c 365 77 (86) 76 (68) NA 2.9 (1.4–5.9) 5.6 0.005
730 67 (74) 73 (65) NA 1.5 (0.8–2.8) 11.1 0.22
Beta-blocker (n = 185)
PDC, mean± SD 365 92.3±13.7 83.6± 21.6 8.4 (3.0–13.8) NA NA 0.003
730 88.5±17.9 82.1± 22.8 6.1 (0.1–12.2) NA NA <0.05
PDC ≥ 80%, n (%) 365 71 (86) 70 (69) NA 2.7 (1.3–5.7) 5.9 <0.01
730 68 (82) 69 (68) NA 2.2 (1.1–4.6) 7.1 <0.05
ACEi/ARB (n = 153)
PDC, mean± SD 365 90.9±17.4 87.6± 18.1 4.7 (−0.8–10.2) NA NA 0.09
730 86.7± 20.6 85.0± 20.9 2.7 (−3.7–9.0) NA NA 0.41
PDC≥ 80%, n (%) 365 59 (87) 64 (75) NA 2.9 (1.1–7.5) 8.3 <0.05
730 52 (76) 59 (69) NA 1.6 (0.7–3.5) 14.3 0.22
MRA (n = 73)
PDC, mean± SD 365 88.6±16.7 87.1±19.9 −0.04 (−9.2–9.1) NA NA 0.99
730 82.4± 21.5 84.5± 22.2 −4.1 (−14.8–6.7) NA NA 0.45
PDC≥ 80%, n (%) 365 26 (72) 28 (76) NA 0.6 (0.2–1.9) – 0.37
730 22 (61) 27 (73) NA 0.5 (0.2–1.4) – 0.16
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; NA, not applicable; NNT, number needed
to treat; PDC, proportion of days covered; PEP, primary efficacy endpoint; SD, standard deviation.
aANCOVA adjusted for baseline adherence (PDC).
bLogistic regression adjusted for PDC at baseline.
cBased on the three groups of heart failure medication classes of interest: beta-blockers, ACEi/ARB, and MRAs; patients with a PDC ≥ 80% are classified as adherent.
For 35 patients [20 (18%) of the pharmacy care and 15 (12%)
of the usual care group] we were unable to calculate a PDC. Rea-
sons included criteria to calculate a PDC not fulfilled, withdrawal
of informed consent (n = 11), or claims data not provided (n = 4).
Compared to the 202 patients for whom a PDC was calculated,
these individuals showed no relevant differences (online supple-
mentary Table S1).
Main efficacy outcomes
The data show a significant improvement for the primary endpoint,
adherence to three HF medication classes within 365 days, in the
pharmacy care compared to the usual care group (mean difference
5.7% [95% confidence interval (CI) 1.6–9.8]; P = 0.007) (Table 2
and Figure 2A). The proportion of patients with a mean PDC≥ 80%
increased from 44% to 86% in the pharmacy care and from 42% to
68% in the usual care group, resulting in a 18% points difference
[OR 2.9, 95% CI 1.4–5.9, P = 0.005; number needed to treat
(NNT) 5.6] (Table 2 and Figure 2B).
Secondary efficacy outcomes
Adherence to three CHF medications within 730 days
post-randomization remained higher in the pharmacy care
compared to the usual care group, but this difference was not ..
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.. statistically significant (mean difference 3.4%, 95% CI −1.2 to 8.1;
P = 0.15) (Table 2 and Figure 2A).
Baseline adjusted adherence to beta-blockers was significantly
improved in the pharmacy care compared to the usual care group,
both within 365 and 730 days (difference 365 days: 8.4%, 95% CI
3.0–13.8, P = 0.003; difference 730 days: 6.1%, 95% CI 0.1–12.2,
P< 0.05) (online supplementary Figure S1). Within 365 days, the
proportion of patients with a PDC ≥ 80% were 86% vs. 69%, a
difference between the cohorts of 17% points (OR 2.7, 95% CI
1.3–5.7, P< 0.01; NNT 5.9).Within 730 days, the frequencies were
82% vs. 68%, a difference of 14% points (OR 2.2, 95% CI 1.1–4.6,
P< 0.05; NNT 7.1) (Table 2 and Figure 2B).
For ACEi/ARB there was a non-significantly higher adherence
within 365 and 730 days (adjusted difference at 365 days: 4.7%,
95% CI −0.8 to 10.2, P = 0.09). The proportion of patients with
a PDC ≥ 80% within 365 days was significantly higher in the phar-
macy care group (OR 2.9, 95% CI 1.1–7.5], P< 0.05; NNT 8.3)
compared to usual care (Table 2 and Figure 2B). Changes in medi-
cation adherence for MRA were not significant (Table 2).
Sensitivity analyses
In all subgroups examined,10 the treatment effect for the primary
efficacy endpoint was preserved. A consistent improvement in
365-day medication adherence in patients receiving pharmacy care
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 (A) Boxplots of adherence to three heart failure medication classes within 365 days (primary endpoint) and 730 days compared
to baseline (183 days prior to randomization). The treatment effects are shown with the 95% confidence intervals. The green horizontal
line represents the cut-off for classifying a patient adherent [proportion of days covered (PDC)≥ 80%]. (B) Proportion of adherent patients
(PDC≥ 80%) for three heart failure medication classes (mean PDC), and separately for beta-blockers and angiotensin-converting enzyme
inhibitors/angiotensin receptor blockers (ACEi/ARB) within 365 and 730 days compared to baseline (183 days prior to randomization). Shown
are the odds ratios (OR) and the absolute percentage differences (Δ) between both groups for the significant effects.
when compared with usual care was demonstrated. For all sub-
groups, there was no significant interaction (Figure 3).
Quality of life, depression, Patient Global
Assessment
Improvement in QoL was more pronounced in the pharmacy
care group after 1 year and was significantly better after 2 years
[difference in MLHFQ scores −7.8 points (−14.5 to −1.1),
P = 0.02], compared to the usual care group (Figure 4). ..
..
..
..
..
..
..
..
..
..
..
..
..
.. Changes in PHQ-9 and PGA scores were not statistically differ-
ent between groups at 12 and 24months compared to baseline.
Safety outcomes
During 365 days post-randomization, eight patients in each group
died (7% and 6%, respectively). Until the end of the study, 20 (18%)
and 27 (21%) patients died in the pharmacy care and usual care
groups, respectively. There was no significant difference between
the pharmacy care and usual care groups in the days lost due
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Forest plot of sensitivity analyses for the primary efficacy endpoint. Shown are data of baseline-adjusted changes of the mean
proportion of days covered for three heart failure (HF) medication classes, using ANCOVA analyses with each subgroup as a covariate, and
treatment and the interaction between treatment and subgroup as covariates. The point estimate and the 95% confidence intervals (CI)
are stated for each subgroup. The P-values of the interaction term (treatment and subgroups) are presented. ACEI, angiotensin-converting
enzyme inhibitor; ARB, angiotensin receptor blocker; BB, beta-blocker; LVEF, left ventricular ejection fraction; MLHFQ, Minnesota Living with
Heart Failure Questionnaire; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; PHQ-9, 9-item Patient Health
Questionnaire.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 4 Change in quality of life (QoL) measured by the
Minnesota Living with Heart Failure Questionnaire global score
at 365 and 730 days. Shown are the mean changes to baseline and
the intervention effects (each with 95% confidence intervals).
to unplanned cardiovascular hospitalizations or death of any cause
in the 365 days following randomization or any other of the
morbidity or mortality endpoints. During follow-up until the end
of the study, there was a numerically higher number of deaths in the
usual care group (Table 3). The Nelson–Aalen plot of time to first
event (all-cause death or unplanned cardiovascular hospitalization)
during 365 days post-randomization is shown in Figure 5.
Discussion
Poor medication adherence represents a major problem but
provides a major opportunity to improve outcomes in patients
with HF at the same time. Convincing evidence for effective inter-
ventions to improve adherence from prospective, randomized
studies is lacking. The PHARM-CHF intervention improved mean
adherence to three HF medications combined and the proportion
of adherent patients (PDC≥ 80%). The intervention led to a
clinically meaningful improvement in QoL and was safe with regard ..
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.. to unplanned cardiovascular hospitalizations or death of any causes.
The analysis of all events that occurred until the end of the study
showed a slight numerically higher number of deaths in the usual
care group.
To our knowledge, PHARM-CHF is the first pharmacy-based
RCT in ambulatory care of elderly HF patients investigating the
impact of a multifaceted, interdisciplinary intervention. Although
the overall intervention effect on the mean PDC across three HF
medication classes was less than the assumed 10% for the sample
size calculation, patients in the pharmacy care group had a three-
fold higher likelihood to achieve a PDC≥ 80%, which is a broadly
accepted threshold for being classified as adherent, compared
to the usual care group. The effects were most pronounced for
beta-blockers and to a lesser extent for ACEi/ARB. The number
of patients receiving MRAs was too small to show a significant
difference.
Several systematic reviews have sought to identify the most
effective interventions for improving medication adherence.8,13
Despite differences in methodologies, the main findings have been
consistent: only multifaceted and continuous interventions, com-
bining several different elements, have the potential to improve
adherence. However, a number of previous studies in cardiovascu-
lar patients failed to demonstrate a significant effect on medication
adherence. The HeartStrong RCT tested whether a system of
medication reminders using financial incentives and social support
applied for 12months delays subsequent vascular events in patients
following acute myocardial infarction compared with usual care.
Medication adherence (mean PDC for statins, beta-blockers, and
antiplatelet agents) was low and did not differ between the control
(42%) and intervention cohorts (46%).14 The two-arm pragmatic
cluster-randomized controlled STIC2IT trial enrolled patients with
suboptimal hyperlipidaemia, hypertension, or diabetes disease con-
trol, who were non-adherent to prescribed medications for these
conditions (mean baseline PDC from pharmacy claims data was
57%). A multicomponent intervention using telephone-delivered
behavioural interviewing by trained clinical pharmacists, text
messaging, pillboxes, and mailed progress reports was compared
Table 3 All-cause deaths and unplanned cardiovascular hospitalizations during 365-day follow-up and until end of the
study
Events Pharmacy care
(n = 110)
Usual care
(n = 127)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
365-day follow-up
All-cause deaths, n (%) 8 (7) 8 (6) 0.77
Unplanned CV hospitalizations, n 47 48 –
Days lost due to unplanned CV hospitalizations and deatha, mean (95% CI) 24.8 (10.6–38.9) 16.5 (6.1–26.8) 0.70
Percentage days lost due to unplanned CV hospitalizations and death, mean (95% CI) 6.78 (2.91–10.66) 4.51 (1.67–7.35) 0.70
Until end of the study
All-cause deaths, n (%) 20 (18) 27 (21) 0.55
Unplanned CV hospitalizations, n 91 93 –
All events (hospitalizations of any cause and deaths), n 253 266 –
CI, confidence interval; CV, cardiovascular.
aPrimary safety endpoint.
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Figure 5 Nelson–Aalen plot for time to first event (all-cause death or unplanned cardiovascular hospitalization) during 365-day follow-up.
CI, confidence interval.
to usual care. The intervention was associated with a 10% increase
in adherence, but did not change clinical outcomes.15
A pharmacist care programme combining education and coun-
selling with the preparation of medicines in time-specific punch
cards increased medication adherence to 97% measured by pill
count. This improvement was associated with improved blood
pressure and lipid values. However, 6 months after randomization,
medication adherence decreased to 69% among those patients
assigned again to usual care.16 In accordance with this study, a
multifaceted intervention comprising pharmacist interventions,
education, interdisciplinary care, and voice messaging increased
medication adherence in the year after an acute coronary syn-
drome with a 15% difference in the proportion of patients with
a mean PDC≥ 80%. Mean PDC was 7% higher in the inter-
vention group.17 Herein, a greater proportion of patients on
intervention were adherent to clopidogrel, statins, and ACEi/ARB
therapies, but not to beta-blockers. In the HF population included
in PHARM-CHF, adherence to beta-blockers was markedly
improved, suggesting that clinical trials addressing adherence in
specific patient populations are needed.
A 9-month intervention provided by one pharmacist at a single
study site improved medication adherence by 11% (measured by
electronic monitoring) but was no longer significantly different
during the 3months post-study phase of the trial.18 These data
confirm that poor adherence cannot be persistently ‘cured’; it
decreases after stopping the interventions to improve adherence,
indicating a need for a continuous strategy.
Heart failure patients are often symptomatic and have a poor
QoL. Alleviating symptoms and improving well-being is important.2
However, very few RCTs have provided evidence with regard to
improvements in QoL. A recent systematic review on disease
management interventions for HF concluded that clinic-based
interventions may result in little or no difference in QoL.19 In
PHARM-CHF, QoL improved in both groups by 12months with no
significant group difference. QoL further improved in the second
year in the pharmacy care group while deteriorating in the usual
care group. Compared to the generally modest improvement of
QoL by other interventions, including device therapy, the 7.8 points ..
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.. change in the MLHFQ global score in favour of pharmacy care
is of significant clinical importance.20 This positive effect on QoL
in the intervention group probably did not relate to medication
adherence only as the control group was likewise adherent at
2 years (PDC≥ 80%). We therefore assume an effect of constant
support by study pharmacists and physicians, which may explain the
increasing difference to the usual care group over time.
Limitations
The relevant improvement in medication adherence in the usual
care group was unexpected and could have affected the differ-
ence to the effect of the intervention on the primary efficacy
endpoint. By design, patients of the control arm were unknown
to the pharmacies, minimizing contamination but at the same time
limiting the availability of detailed information. We cannot there-
fore exclude the possibility of cross over with regard to general
awareness, the use of dosing aids and/or physician interventions
to optimizing pharmacotherapy in the usual care group. A cer-
tain degree of improved monitoring and care of patients during
a RCT when compared to ‘real-world’ usual care is unavoid-
able. The effect of the intervention on the PDC as a continuous
variable is quantitatively smaller than the effect on the propor-
tion of patients with a PDC≥ 80%. The 80% cut-point for PDC
is widespread practice and was used because it is associated
with improved clinical outcomes for several medications/diseases
including HF.5,21–23 Unfortunately, we were unable to calculate a
PDC for 35 patients. However, these individuals did not differ in
any relevant characteristic available and the power to detect a 10%
difference in mean adherence was preserved by the remaining num-
ber of participants. Notably, this study was not powered to explore
the effects on morbidity and mortality.
Conclusion
A pharmacy-based interdisciplinary intervention improved mean
adherence to three HF medication classes and the proportion
of adherent patients, and led to clinically important improvements
in QoL. For these important aims, pharmacy care represents
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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a valuable addition to the comprehensive care for HF patients.
Morbidity and mortality effects need to be scrutinized in an
adequately powered RCT.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Figure S1. Boxplots of adherence to beta-blockers within
365 days and 730 days compared to baseline (183 days prior to
randomization). The treatment effects are shown with the 95%
confidence intervals. The green horizontal line represents the
cut-off for classifying a patient adherent (proportion of days
covered≥ 80%).
Table S1. Characteristics of participants with or without calcula-
tion of proportion of days covered.
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Table S1      Characteristics of participants with or without PDC calculation  
 
Characteristic With PDC (n=202) 
Without PDC  
(n=35) 
P-value 
Demographics 
   Age, mean ± SD, years 73.9 ± 7.0 75.5 ± 6.8 0.20 
   Female sex, n (%) 78 (39%) 13 (37%) 0.87 
Physical examination, mean ± SD 
   BMI, kg/m2 29.2 ± 5.0 28.9 ± 5.1 0.75 
   Systolic blood pressure, mm Hg 128.6 ± 16.8 127.0 ± 12.2 0.52 
   Diastolic blood pressure, mm Hg 76.5 ± 10.0 77.7 ± 12.4 0.61 
   Heart rate, min-1 74.7 ± 13.5 74.8 ± 13.8 0.97 
Heart failure characteristics 
   Heart failure aetiology, n (%)  0.72 
     Ischemic  107 (53%) 19 (54%)  
     Non-ischemic 74 (37%) 11 (31%)  
     Other 21 (10%) 5 (14%)  
   LVEF, mean ± SD, %  46.9 ± 14.6 45.4 ± 14.4 0.62 
     LVEF <40%, n (%) 50 (25%) 8 (23%) 
0.15      LVEF 40–49%, n (%) 71 (35%) 18 (51%) 
     LVEF ≥50%, n (%) 81 (40%) 9 (26%) 
   NYHA, functional class, n (%)   
     I/II 82 (41%) 15 (43%) 
0.80 
     III/IV 120 (59%) 20 (57%) 
Time since last hospitalization for heart  
failure, mean ± SD, years  0.36 ± 0.83 0.23 ± 0.51 0.21 
Medical history 
  Different co-morbidities, mean ± SD  7.0 ± 2.3 7.6 ± 2.5 0.16 
  Hypertension, n (%) 196 (97%) 35 (100%) 0.31 
  CAD, n (%) 139 (69%) 26 (74%) 0.52 
  Hyperlipidaemia, n (%) 160 (79%) 25 (71%) 0.31 
  Cardiomyopathy, n (%) 76 (38%) 15 (43%) 0.56 
  Valvular disease, n (%) 92 (46%) 17 (49%) 0.74 
  Atrial fibrillation, n (%) 119 (59%) 25 (71%) 0.16 
  Chronic renal disease, n (%) 77 (38%) 18 (51%) 0.14 
  Diabetes mellitus, n (%) 108 (53%) 17 (49%) 0.59 
  Myocardial infarction, n (%) 49 (24%) 16 (46%) 0.009 
  Stroke/TIA, n (%) 31 (15%) 9 (26%) 0.13 
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  Sleep apnea, n (%) 22 (11%) 4 (11%) 0.93 
  Depression, n (%) 31 (15%) 6 (17%) 0.79 
  COPD, n (%) 54 (27%) 11 (31%) 0.57 
Treatments 
  ICD or CRT, n (%) 65 (32%) 10 (29%) 0.67 
Medication, n (%) 
  ACEi/ARB  168 (83%) 26 (74%) 0.21 
  Beta-blocker  194 (96%) 27 (77%) <0.0001 
  MRA  88 (44%) 13 (37%) 0.48 
  Diuretic 202 (100%) 35 (100%)  
  No. drug packages, mean ± SD 8.7 ± 3.0 9.5 ± 3.2 0.22 
  No. drug substances, mean ± SD  9.2 ± 3.2 9.8 ± 3.3 0.36 
  No. single doses/day, mean ± SD  10.9 ± 4.0 11.0 ± 4.5 0.86 
  No. drug intakes/day, mean ± SD  2.9 ± 0.7 2.8 ± 0.7 0.87 
Laboratory measurements, mean ± SD  
  Potassium, mmol/L  4.42 ± 0.68 4.41 ± 0.59 0.89 
  Serum creatinine, mg/dL  1.33 ± 0.65 1.44 ± 0.72 0.44 
  eGFR, mL/min  62.0 ± 24.8 57.3 ± 27.1 0.34 
  LDL-cholesterol, mg/dL  110.3 ± 39.8 100.5 ± 35.6 0.17 
  Blood urea nitrogen, mg/dL  55.8 ± 27.2 56.6 ± 23.9 0.86 
Quality of life (MLHFQ score),  
mean ± SD    40.5 ± 21.0   46.0 ± 22.6 0.20 
Depression (PHQ-9 score), mean ± SD 6.8 ± 5.2    7.6 ± 6.0 0.44 
 
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass 
index; BUN, blood urea nitrogen; CAD, coronary artery disease; COPD, chronic obstructive 
pulmonary disease; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration 
rate; HF, heart failure; ICD, implantable cardioverter-defibrillator; LDL, low-density lipoprotein; 
LVEF, left ventricular ejection fraction; MLHFQ, Minnesota Living with Heart Failure Questionnaire; 
MRA, mineralocorticoid receptor antagonists; NYHA, New York Heart Association (functional class); 
PDC, percentage of days covered; PHQ-9, 9-Item Patient Health Questionnaire; SD, standard 
deviation; TIA, transient ischemic attack.   
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Figure S1 Boxplots of adherence to beta-blockers within 365 days and 730 days compared to 
baseline (183 days prior randomization). The treatment effects are shown with the 
95% confidence intervals. The green horizontal line represents the cut-off for 
classifying a patient adherent (PDC ≥80%). 
 
 
 
 
  
 
 
 
